<DOC>
	<DOC>NCT01517698</DOC>
	<brief_summary>This multi-center, randomized, double-blind, placebo-controlled, parallel-group study will investigate the efficacy and safety of RO4917523 in adolescent and adult patients with fragile X syndrome. Patients will be randomized to receive oral doses of 0.5 mg or 1.5 mg of RO4917523, or matching placebo once daily. The anticipated time on study treatment is 12 weeks.</brief_summary>
	<brief_title>A Study of RO4917523 in Patients With Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Adult and adolescent patients, 1450 years of age Diagnosis of fragile X syndrome with a confirmed fragile X mental retardation 1 (FMR1) full mutation and qualifying scores on the Aberrant Behavior Checklist (ABC) and CGIS Patients must agree to either remain completely abstinent or to use two effective contraceptive methods during and 3 weeks after the study Previous treatment with another metabotropic glutamate (mGLU) receptor antagonist within 18 months or with RO4917523 Participation in a clinical trial involving an investigational (unapproved) drug within 3 months or 5 times the halflife (whichever is longer) before start of this study Any uncontrolled, unstable clinically significant psychiatric condition other than fragile X syndrome History of suicidal behavior</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>